Lifeward

Slow Medicare Reimbursements Will Undermine Efficiency But Foster Resilience

AnalystLowTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

31 Aug 25

Updated

31 Aug 25

AnalystLowTarget's Fair Value

US$1.00

38.3% undervalued

31 Aug

US$0.62

-81.1%

-2.0%

-81.1%

-2.0%

Edit anytime before Aug 31 10:47 PM. Then post Updates to your followers.

Author's Valuation

US$1.0

38.3% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$1.0

38.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

38.83%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.43%

Calculation

US$1.72m

Earnings '28

26.24x

PE Ratio '28

US$45.22m

Market Cap '28

US$45.22m

Market Cap '28

34.50m

No. shares '28

US$1.31

Share Price '28

US$1.31 Share Price '28

Discounted to 2025 @ 9.43% p.a.

US$1.00

Fair Value '25